Adults over the age of 60 now have two RSV vaccines to choose from in the U.S. and Europe. A new antibody treatment is available to prevent infants from infections, too.
So far, Pfizer is the only drugmaker to reach regulators with a candidate for use in pregnant people, which could give another option for protecting newborns. GSK, which won approval of its RSV vaccine in older adults, was also testing a candidate in pregnant women up until last year, when it halted testing for a safety review.
